GLP1R and type 2 diabetes mellitus: These analyses included alternative definitions of weight outcomes, a shorter follow-up period and stricter inclusion criteria for BS, adjustments for T2D status, subgroup analysis for GLP1-RA medication and BS patients, and testing different statistical models.